Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 25,000 Shares

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 25,000 shares of the business’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $80.17, for a total transaction of $2,004,250.00. Following the completion of the sale, the director directly owned 830,073 shares of the company’s stock, valued at approximately $66,546,952.41. This trade represents a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Liquidia Price Performance

Shares of LQDA stock opened at $79.47 on Thursday. The company has a market capitalization of $7.07 billion, a P/E ratio of 567.68 and a beta of 0.55. The company’s 50-day simple moving average is $63.33 and its two-hundred day simple moving average is $46.35. Liquidia Corporation has a one year low of $12.88 and a one year high of $82.96. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.11. The firm had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The company’s quarterly revenue was up 4187.1% compared to the same quarter last year. As a group, equities analysts anticipate that Liquidia Corporation will post 3.02 EPS for the current year.

Hedge Funds Weigh In On Liquidia

Several institutional investors have recently bought and sold shares of LQDA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Liquidia by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock worth $556,000 after buying an additional 1,700 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Liquidia by 10.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after acquiring an additional 82,955 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Liquidia by 15.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after acquiring an additional 16,022 shares in the last quarter. Creative Planning increased its holdings in shares of Liquidia by 40.7% in the 2nd quarter. Creative Planning now owns 26,840 shares of the company’s stock valued at $334,000 after acquiring an additional 7,765 shares during the period. Finally, Legal & General Group Plc increased its holdings in shares of Liquidia by 13.4% in the 2nd quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock valued at $1,174,000 after acquiring an additional 11,111 shares during the period. 64.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LQDA has been the subject of several research reports. Wall Street Zen cut Liquidia from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 27th. Oppenheimer set a $75.00 price target on Liquidia in a research note on Friday, June 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a report on Tuesday, April 21st. Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. Finally, BTIG Research upped their price objective on shares of Liquidia from $59.00 to $109.00 and gave the stock a “buy” rating in a research note on Monday, June 22nd. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $68.88.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).